Molecular therapies in hepatocellular carcinoma: What can we target?

Digestive Diseases and Sciences

Volumn 59, Issue 8, 2014, Pages 1688-1697

  Galuppo, Roberto ^a   Ramaiah, Dinesh ^a   Ponte, Oscar Moreno ^a   Gedaly, Roberto ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Epidermal growth factor; Hepatocellular carcinoma; Liver cancer stem cells; Ras Raf MAPK; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; APITOLISIB; BAVITUXIMAB; BETA CATENIN; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; EVEROLIMUS; GEDATOLISIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PANOBINOSTAT; PERIFOSINE; RAF PROTEIN; RAMUCIRUMAB; RAPAMYCIN; RAS PROTEIN; REFAMETINIB; RESMINOSTAT; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; WNT PROTEIN; YTTRIUM 90;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL ACTIVATION; CELL PROLIFERATION; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DNA METHYLATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84905571686     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3058-x     Document Type: Review

References (65)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917. (Pubitemid 37518510)
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127.
4. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704-713.
5. Chen C, Yang H, Yang W, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111-121. (Pubitemid 351899021)
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638. (Pubitemid 36459468)
7. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468. (Pubitemid 38182303)
8. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-380. (Pubitemid 43343895)
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
10. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-1763. (Pubitemid 351615415)
11. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol Baltim Md. 2005;42:1208-1236. (Pubitemid 43112690)
13. Clark HP, Carson WF, Kavanagh PV, Ho CPH, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma1. Radiographics. 2005;25:S3-S23. (Pubitemid 41686059)
14. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatol Baltim Md. 2003;37:429-442. (Pubitemid 36152543)
16. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-1335.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
18. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
19. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200. (Pubitemid 40781071)
20. European Association for the Study of the Liver, and European Organization for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
21. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55-76.
22. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene . 2006;25:3778-3786. (Pubitemid 43980473)
23. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410-1426.
24. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-255.
25. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006;1:7-9. (Pubitemid 47164015)
26. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284.
27. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779-827.
28. Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res. 2004:10:4254s-4257s. (Pubitemid 38812457)
29. Caponigro F. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs. 2002;13:891-897.
30. Cantrell DA. GTPases and T cell activation. Immunol Rev. 2003;192:122-130. (Pubitemid 36613328)
31. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117-1134.
32. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14:3136-3145.
33. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10:842-857.
34. Chong H, Vikis HG, Guan K-L. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463-469. (Pubitemid 36292166)
35. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26:3227-3239. (Pubitemid 46763017)
36. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992;258:478-480.
37. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-119.
38. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689. (Pubitemid 19213607)
39. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153-208. (Pubitemid 32098004)
40. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta. 2003;1603:47-82. (Pubitemid 36262941)
41. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
42. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47. (Pubitemid 37328806)
43. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844. (Pubitemid 23132159)
44. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25. (Pubitemid 27076453)
45. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620.
46. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385-1392.
47. Tseng P-L, Tai M-H, Huang C-C, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008;98:349-357.
48. Gavert N, Ben-Ze'ev A. Beta-Catenin signaling in biological control and cancer. J Cell Biochem. 2007;102:820-828. (Pubitemid 350036922)
49. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1-24. (Pubitemid 36627817)
50. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci. 2006;11:1901-1915.
51. Zucman-Rossi J, Jeannot E, Nhieu JTV, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatol Baltim Md. 2006;43:515-524.
52. Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194.
53. Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol BioSyst. 2010;6:44-54.
54. Yin L, Velazquez OC, Liu Z-J. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80:690-701.
55. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Downregulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483-493.
56. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747-2761. (Pubitemid 350070721)
57. Yang J-M, Chen W-S, Liu Z-P, Luo Y-H, Liu W-W. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. J Gastroenterol Hepatol. 2003;18:296-301. (Pubitemid 36513158)
58. Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:1435-1448.
59. Zhu AX. New agents on the horizon in hepatocellular carcinoma. Ther Adv Med Oncol. 2013;5:41-50.
60. Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2:135-164.
61. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM. PKI-587 and sorafenib targeting PI3 K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res. 2012;176:542-548.
62. Gedaly R, Angulo P, Chen C, et al. The role of PI3 K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res. 2012;32:2531-2536.
63. Home-ClinicalTrials.gov. http://clinicaltrials.gov/. Epub. 02/13/2013.
64. Lachenmayer A, Toffanin S, Cabellos L, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343-1350.
65. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting Ras/Raf/MAKP and Wnt/β-Catenin Pathways. Anticancer Res (in press).